The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Ting Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for C…. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Receptor, Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Langerhans cell histiocytosis (LCH) is a rare hematologic neoplasm characterized by the clonal proliferation of Langerhans‐like cells. Colony‐stimulating factor 1 receptor (CSF1R) is a membrane‐bound receptor that is highly expressed in LCH cells and tumor‐associated macrophages. In this study, a soluble form of CSF1R protein (sCSF1R) was identified by plasma proteome profiling, and its role in evaluating LCH prognosis was explored. We prospectively measured plasma sCSF1R levels in 104 LCH patients and 10 healthy children using ELISA. Plasma sCSF1R levels were greater in LCH patients than in healthy controls ( p < .001) and significantly differed among the three disease extents, with the highest level in MS RO + LCH patients ( p < .001). Accordingly, immunofluorescence showed the highest level of membrane‐bound CSF1R in MS RO + patients. Furthermore, the plasma sCSF1R concentration at diagnosis could efficiently predict the prognosis of LCH patients treated with standard first‐line treatment (AUC = 0.782, p < .001). Notably, dynamic monitoring of sCSF1R levels could predict relapse early in patients receiving BRAF inhibitor treatment. In vitro drug sensitivity data showed that sCSF1R increased resistance to Ara‐C in THP‐1 cells expressing ectopic BRAF ‐V600E. Overall, the plasma sCSF1R level at diagnosis and during follow‐up is of great clinical importance in pediatric LCH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Beijing Key Laboratory of Pediatric Hematology-Oncology, Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
- Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
ORCID-Profile: Chan-Juan Wang, Rui Zhang, Zhi-Gang Li
Förderung
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- Beijing Natural Science Foundation
- Funding for Reform and Development of Beijing Municipal Health Commission
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhu, T., Wang, C. J., Lian, H. Y., Ma, H. H., Wang, D., Wang, T. Y., Zhang, R., Cui, L., & Li, Z. G. (2024). The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30970
Vancouver
Zhu T, Wang CJ, Lian HY, Ma HH, Wang D, Wang TY, et al. The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30970
BibTeX
@article{Zhu2024,
author = {Zhu, Ting and Wang, Chan-Juan and Lian, Hong-Yun and Ma, Hong-Hao and Wang, Dong and Wang, Tian-You and Zhang, Rui and Cui, Lei and Li, Zhi-Gang},
title = {The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30970}
}
EUVIMED